Ishwara Sankara, MD
Neurocritical Care · Fort Worth, TXNPI 1316154370
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,165 of the $1,703 with a category attached, or 68.4%. Astrazeneca UK Limited accounts for 84.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,443 and has fallen 89.8% since, to $147 in 2024.
Across 17 payments — averaging $100.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$1K
- UCB, Inc.$155
- Integra Lifesciences Corporation$41
- Aesculap, Inc.$17
- Bayer$16
- Medtronic$16
- plus $15 from 1 others
Across 3 payments — averaging $33,756 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$101K
What the payments were for
- Travel & lodging$1,16568%
- Food & beverage$53932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 10 | $1,443 |
| UCB, Inc. | 2 | $155 |
| Integra Lifesciences Corporation | 1 | $41 |
| Aesculap, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Medtronic | 1 | $16 |
| Si-bone, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,703 in reported general payments places this provider in the 80th percentile of 46 neurocritical care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurocritical care in Fort Worth
- Claudia PerezFort Worth$2K
- Zakraus MahdaviFort Worth$881
- Mohamed OsmanFort Worth$550
- Jay YaoFort Worth$60
- Ali SeifiSan Antonio$58K
- Ashutosh MahapatraHouston$27K
- Faheem SheriffEl Paso$12K
- Ritvij BowryHouston$11K
- Huimahn ChoiHouston$2K
- Muhammad Ubaid HafeezHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.